Patient-Consented Data
from Lived Experiences.
Real, longitudinal data collected with full patient consent, enabling use in research from the outset.
Our ability to rapidly re-consent participants for new studies and programmes provides unmatched flexibility for follow-up research, pilots, and protocol adaptations, supporting faster, regulatory-grade evidence generation.
Insights That Drive Decisions.
Optivra provides access to large-scale, longitudinal datasets collected across multiple geographies and therapy areas.
1M+ patient records
Across priority conditions
30+ harmonised sources
Integrated and standardised for real-world use
4 global regions
Including Europe, Africa, India and the United States
Optivra enables partners to transform complex, multi-source data into actionable insights that power clinical development, regulatory submissions, and market access. Through advanced analytics, causal modelling, and disease-area expertise, we support the rapid generation of high-quality evidence across the product lifecycle. Whether building synthetic control arms, tracking real-world outcomes, or supporting post-marketing studies, our capabilities help accelerate timelines and increase confidence in decision-making.
What We Do Well | Life Sciences Offerings
01
Real-World Evidence Insight that Drive Solutions.
02
Patient-centered, Bespoke Solutions from a Top Team of Experts.
03
Data Dissemination and Visualisation to Make an Impact with Stakeholders.
Demonstrated Impact on Evidence Generation.
Accelerating Patient Find
Across Rare & Specialist Conditions.
Accelerated Patient Identification
Advanced analytics and federated data matching enable earlier patient discovery across complex and rare diseases, supporting faster trial and registry development.
Targeted Engagement and Pre-Screening
Optivra’s clinical engagement pathways connect identified patients with trusted clinicians, ensuring relevance, eligibility, and consent from the start.
Research & Data That
Feeds Back
Each patient journey is linked back to
de-identified real-world evidence, creating
a continuous loop between recruitment, outcomes, and ongoing research.
Accelerating Patient Identification
Across Rare & Specialist Conditions.
Accelerated Patient Identification
We identify potential patients through real-world and clinical data signals, including EHR, genomics, and wearable inputs to locate individuals who may meet study or registry criteria early in their journey.
Confirmed Diagnosis & Screening
Once identified, patients are clinically validated through diagnosis confirmation and eligibility screening. This ensures every participant meets protocol requirements before enrolment and that baseline data are accurate and complete.
Retention & Continuous Insight
After onboarding, participants remain engaged through digital follow-up and outcome tracking. Longitudinal, de-identified data feed back into research, creating an ongoing evidence loop that strengthens every subsequent study.
Accelerated Patient Identification
We identify potential patients through real-world and clinical data signals, including EHR, genomics, and wearable inputs to locate individuals who may meet study or registry criteria early in their journey.
Confirmed Diagnosis & Screening
Once identified, patients are clinically validated through diagnosis confirmation and eligibility screening. This ensures every participant meets protocol requirements before enrolment and that baseline data are accurate and complete.
Retention & Continuous Insight
After onboarding, participants remain engaged through digital follow-up and outcome tracking. Longitudinal, de-identified data feed back into research, creating an ongoing evidence loop that strengthens every subsequent study.
An Integrated Ecosystem
For Data, Analytics, and Science.
Data Infrastructure
Access large-scale, longitudinal, regulatory-grade datasets across multiple regions and therapy areas.
Advanced Analytics
Apply causal inference, machine learning, and disease models to generate high-quality real-world evidence.
Scientific & Regulatory Expertise
Design studies that meet regulatory standards, from synthetic controls to post-authorisation research.
Secure, Scalable Platform
Work within a single, privacy-preserving environment built for global collaboration and governance.
Patient Support Programme
Scalable, patient-centred support through remote monitoring, wearables, and coaching. Integrating clinical, ePRO, and wearable data with GCP-accredited monitoring. Tailored engagement protocols improve adherence, outcomes, and reduce healthcare burden.
Patient Find
Accelerating patient identification to optimise therapeutic pathways and clinical trial enrolment. Using EMR, wearable data, and machine learning profiling to identify patients efficiently, shorten time to diagnosis, and expand cohorts for faster enrolment.
Ethically Approved Studies
Maximising impact through evidence-based research across therapeutic areas. Ethically approved programmes combine patient engagement, continuous data capture, and real-time outcomes to generate evidence for regulatory submissions and care strategies.
Evidence Development
Development of regulatory-grade evidence, health economic models, and validated clinical pathways. Optivra’s datasets and analytical frameworks support real-world studies and inform clinical and regulatory strategies.
Stakeholder Engagement
Alignment with patient groups, clinical experts, and commissioners to shape assumptions, inform study design, and strengthen submissions. Optivra enables evidence generation that reflects both real-world needs and regulatory requirements.
Post-Launch Evidence
Ongoing data collection, re-evaluation readiness, and outcome tracking within Optivra’s Clinical Research Environment. This ensures continuous evidence generation to support label expansions, reimbursement, and long-term impact assessments.
Data Generation
Access and integrate diverse real-world data sources including electronic health records, claims data, and patient registries, to capture outcomes reflective of real-world clinical practice.
Evidence Generation
Translate real-world data into robust, regulatory-grade evidence to demonstrate the safety, effectiveness, and value of therapies to regulators, payers, and healthcare professionals.
Study Design & Scientific Solutions
Develop and execute real-world and observational study designs, support informed decision-making throughout the therapy life cycle,from early launch through commercialisation and post market surveillance
Specific Methodologies
Deliver non-interventional studies, chart reviews, and patient-centred research using validated methods, proprietary data sources, and advanced analytical platforms.
Scientific and Data Advantages
That Set Us Apart.
Rich, Multi-Modal Real-World Data
Deep, longitudinal data drawn from complete patient medical records, including EHR, and enriched with patient-reported information and wearable data, enabling robust evidence generation for life sciences.
Provenance and Quality Assured
Source data provenance is maintained throughout, ensuring regulatory-grade integrity and traceability for every dataset used in research.
Longitudinal Follow-Up at Scale
With access to thousands of patients, we can conduct follow-up studies and collect additional insights over time to support
longitudinal research.
Broad Condition Coverage
All major haemato-oncology specialties are represented, allowing for comprehensive research across diverse patient populations.
Access to Leading Researchers
Our network includes leading clinicians and academic experts who collaborate to deliver high-quality, regulatory-ready evidence.
Scientific and Data Advantages
That Set Us Apart.
Deep, longitudinal data drawn from complete patient medical records, including EHR, and enriched with patient-reported information and wearable data, enabling robust evidence generation for life sciences.
Source data provenance is maintained throughout, ensuring regulatory-grade integrity and traceability for every dataset used in research.
With access to thousands of patients, we can conduct follow-up studies and collect additional insights over time to support
longitudinal research.
All major haemato-oncology specialties are represented, allowing for comprehensive research across diverse patient populations.
